一项随机对照试验研究了药物坚持工具对心力衰竭患者的影响
Bhupendra Pawar1, Pamila Dua1, Sandeep Seth2
1Pharmacology, All India Institute of Medical Sciences, New Delhi, New Delhi, IND.
Cureus
|October 28, 2025
概括
药物坚持工具 (MAT) 显著改善了心力衰竭患者的药物遵守,生活质量和身体功能. 这项研究强调了综合干预对更好的心力衰竭管理的重要性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 心力衰竭 (HF) 是全球主要的发病率和死亡率原因之一.
- 药物坚持对于管理慢性HF和改善患者结果至关重要.
- 在HF患者中不遵守有严重的后果,需要有针对性的干预措施.
研究的目的:
- 评估药物坚持工具 (MAT) 对改善心力衰竭患者药物坚持和功能能力的影响.
- 评估包括MAT,健康教育和结构化药物治疗方案 (ABCD) 在HF管理中的综合干预措施的有效性.
主要方法:
- 一项前性,开放性,随机对照性研究,涉及200名心力衰竭患者.
- 干预组接受了标准护理,加上ABCD药物治疗方案,健康教育和MAT (Hriday Card,Dhadkan 2应用程序,标有拉链锁).
- 使用Morisky-Green-Levine (MGL) 尺度评估药物坚持;生活质量和身体功能 (例如,爬楼,走500米) 也被评估.
主要成果:
- 基线分析显示了显著的药物不服药 (患者中13%的药物不服药程度低),利尿剂是最常见的不服药药物类别.
- 干预组在MGL得分上表现出显著的改善,这表明药物坚持度有所提高.
- 接受干预的患者也显示了生活质量和身体功能显著改善.
结论:
- 相当一部分心力衰竭患者经历了药物不服药.
- 包括MAT在内的综合干预策略显著改善了HF患者的药物坚持,生活质量和身体功能.
- 可以推MAT作为标准护理的辅助,以优化心力衰竭管理和患者的结果.
相关概念视频
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:22Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:22Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
01:30Heart Failure VII: Nursing Interventions
410
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
410
01:28Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239